These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U. Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386 [Abstract] [Full Text] [Related]
7. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP. Br J Haematol; 2017 Dec; 179(5):739-747. PubMed ID: 29082519 [Abstract] [Full Text] [Related]
8. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma. Kayamori K, Shono K, Onoda M, Yokota A. Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679 [Abstract] [Full Text] [Related]
9. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM. Cancer; 2019 Jun 01; 125(11):1830-1836. PubMed ID: 30707764 [Abstract] [Full Text] [Related]
10. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Lancet Oncol; 2011 May 01; 12(5):460-8. PubMed ID: 21482186 [Abstract] [Full Text] [Related]
14. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. Aoki K, Takahashi T, Tabata S, Kurata M, Matsushita A, Nagai K, Ishikawa T. Leuk Lymphoma; 2013 Nov 01; 54(11):2441-7. PubMed ID: 23452117 [Abstract] [Full Text] [Related]
15. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Cancer; 2016 Oct 15; 122(20):3145-3151. PubMed ID: 27351173 [Abstract] [Full Text] [Related]